EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders

Erhan Kavakbasi, Kevin Rosemann, Mert Yilmaz, Helmut Berndt, Bernhard T Baune

European Archives of Psychiatry and Clinical Neuroscience · 2025

DOI: 10.1007/s00406-025-02041-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Erhan Kavakbasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University Hospital Münster, University of Münster, Albert-Schweitzer-Campus 1, Building A9, 48149, Münster, Germany. erhan…. Hauptthemen laut MEDLINE: Electroconvulsive Therapy, Ketamine, Depressive Disorder, Treatment-Resistant, Suicidal Ideation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum RWTH Aachen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intranasal esketamine (ESK) is a novel therapy option in patients with treatment-resistant depression (TRD). Patients with a history of electroconvulsive therapy (ECT) non-response (ECT+) in the current episode have usually been excluded from previous studies. Data on the effectiveness of ESK in ECT non-responders are sparse.

Methods

In this retrospective study, we investigated the effectiveness of intranasal ESK in real-world inpatients with (ECT+, n = 39) history of ECT non-response compared to patients who have not received an adequate course of ECT in their current episode (ECT-, n = 57). A factorial analysis of variance (ANOVA) has been used to determine the impact of ECT non-response on treatment outcome.

Results

A total of n = 96 patients (mean age 47.0; 52.1% women) with TRD were included in this study. There was a significant main effect of history of ECT non-response on MADRS score in the ANOVA (F = 10.386, p = 0.002). However, there was no significant interaction effect of time (pre-treatment, post-treatment)*history of ECT non-response in current episode (F = 2.166, p = 0.143). The response (34.9% vs. 21.9%, χ2 = 1.498, p = 0.167) and remission rates (24.4% vs. 12.1%, χ2 = 1.861, p = 0.141) were none significantly lower in the ECT + group than in the ECT- group. There was significant improvement in MADRS and BDI-II in the ECT + group. No major safety concerns occurred during the study.

Conclusion

There was no significant impact of ECT non-response on esketamine treatment outcome. Our results support the approach to offer esketamine to ECT non-responders given that the array of treatment alternatives is limited for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electroconvulsive TherapyKetamineDepressive Disorder, Treatment-ResistantSuicidal IdeationOutcome Assessment, Health CareHumansFemaleMaleMiddle AgedAdultRetrospective StudiesAdministration, IntranasalSeverity of Illness IndexAged

Stichwörter der Autor:innen

Electroconvulsive therapyEsketamineMajor depressive disorderNovel antidepressantsTreatment resistant depression

Substanzen

KetamineEsketamine

Autor:innen und Institutionen

  • Department of Psychiatry, University Hospital Münster, University of Münster, Albert-Schweitzer-Campus 1, Building A9, 48149, Münster, Germany. erhan.kavakbasi@uni-muenster.de.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany. erhan.kavakbasi@uni-muenster.de.
  • Department of Psychiatry, University Hospital Münster, University of Münster, Albert-Schweitzer-Campus 1, Building A9, 48149, Münster, Germany.
  • Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia.
  • The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.

Förderung

  • Universitätsklinikum RWTH Aachen

Zitieren

APA

Kavakbasi, E., Rosemann, K., Yilmaz, M., Berndt, H., & Baune, B. T. (2025). Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-025-02041-9

Vancouver

Kavakbasi E, Rosemann K, Yilmaz M, Berndt H, Baune BT. Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-025-02041-9

BibTeX
@article{Kavakbasi2025,
  author = {Kavakbasi, Erhan and Rosemann, Kevin and Yilmaz, Mert and Berndt, Helmut and Baune, Bernhard T},
  title = {Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  doi = {10.1007/s00406-025-02041-9}
}
Kostenlos starten →